This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Kahn and colleagues¹ claimed that after a disagreement between them and the sponsor, they published the incomplete, although generally negative, results of a trial of an immunologic modifier (Remune; The Immune Response Corp [IRC], Carlsbad, Calif) for human immunodeficiency virus (HIV) "to fulfill our responsibility to inform patients of the outcome of this study, and to contribute to their understanding of HIV-1 Immunogen if it was to be studied in another clinical trial." I find that the article is inconclusive for several reasons.

First, while the primary end point of the study was time to HIV progression, the authors only presented HIV progression rate. They did not include true temporal variables, such as mean (or median) time to HIV progression for each treatment group, or time at which a certain proportion of patients experienced HIV progression for each treatment group.

Second, the viral load data could . . . [Full Text of this Article]